ALAlphabet Inc.

Institutional investor · Portfolio as of Q3 2021

Top Holdings43 positions

Checking export access…
Activity:

UIPATH INC

17.6M$925M21.9%$67.93-22.55%
2 qtrssince 2021-Q2
Decreased
0
VERVVERVDelisted

VERVE THERAPEUTICS INC

11M$515.8M12.2%——
2 qtrssince 2021-Q2
Unchanged
0

DEXCOM INC

805,681$440.5M10.4%$52.30+161.39%
9 qtrssince 2019-Q3
Unchanged
0

OSCAR HEALTH INC

24M$418.1M9.9%$26.88-35.31%
3 qtrssince 2021-Q1
Unchanged
0

LYFT INC

6.1M$328.9M7.8%$40.84+31.22%
9 qtrssince 2019-Q3
Unchanged
0

ROBINHOOD MKTS INC

7.7M$323.9M7.7%$42.080.00%
1 qtr
New
97

INVIVYD INC

5.7M$240M5.7%$42.240.00%
1 qtr
New
96

ARCUS BIOSCIENCES INC

4.1M$143M3.4%$9.10+283.19%
9 qtrssince 2019-Q3
Decreased
0

DUOLINGO INC

712,304$118.5M2.8%$166.360.00%
1 qtr
New
79
BHILBHILDelisted

Benson Hill Inc

14.8M$105.2M2.5%——
1 qtr
New
79

LYELL IMMUNOPHARMA INC

5.9M$86.8M2.1%$324.80-8.87%
2 qtrssince 2021-Q2
Unchanged
0
DMDMDelisted

Desktop Metal Inc

11M$79.2M1.9%——
4 qtrssince 2020-Q4
Unchanged
0

SANA BIOTECHNOLOGY INC

2.8M$63.3M1.5%$33.47-32.72%
3 qtrssince 2021-Q1
Unchanged
0

RELAY THERAPEUTICS INC

1.6M$51.8M1.2%$41.74-24.46%
5 qtrssince 2020-Q3
Decreased
0

MONTE ROSA THERAPEUTICS INC

1.5M$32.6M0.8%$22.70-1.85%
2 qtrssince 2021-Q2
Unchanged
0
KRONKRONDelisted

KRONOS BIO INC

1.4M$30.1M0.7%——
4 qtrssince 2020-Q4
Unchanged
0

BEAM THERAPEUTICS INC

321,604$28M0.7%$18.00+383.39%
7 qtrssince 2020-Q1
Decreased
0
BRNSBRNSDelisted
ADR

BARINTHUS BIOTHERAPEUTICS PL

1.7M$26.8M0.6%$14.33+8.86%
2 qtrssince 2021-Q2
Unchanged
0
3.3M$24.3M0.6%——
9 qtrssince 2019-Q3
Unchanged
0
RAPTRAPTDelisted

RAPT THERAPEUTICS INC

710,250$22.1M0.5%——
8 qtrssince 2019-Q4
Decreased
0
$4.2B
AUM
43
Positions
Q3 2021
Filing
HI score · 2.0/5
Quarterly 13F Value Change
+42%Q2'20$2.2B-2%Q3'20$2.1B-2%Q4'20$2.1B+19%Q1'21$2.5B+98%Q2'21$4.9B-14%Q3'21$4.2B
Activity profile
$ moved · Q3'21
New39%Increased0%Decreased52%Exited9%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 3.6 quarters
<1Q23%1-4Q37%1-2Y9%2Y+30%

Alphabet Inc. manages $4.2B across 43 positions as of Q3 2021. Top holdings: PATH (21.9%), VERV (12.2%), DXCM (10.4%). Fund DNA: Concentrated Value. HoldingsIntel Score: 2/5.0.

Q3 2021 Summary

Added HOOD, IVVD, DUOL and 7 more; exited ABNB, WORK and CLOV; trimmed 6, led by PATH (−11.4M shares). Top move: HOOD (NEW, conviction 97). Portfolio: $4.2B across 43 positions.

Top holdings by portfolio weight

Total AUM$4B
PATH21.94%
VERV12.24%
DXCM10.45%
OSCR9.92%
LYFT7.80%
HOOD7.68%
IVVD5.69%
RCUS3.39%
DUOL2.81%
BHIL2.50%
Other2.06%

Portfolio allocation by GICS sector

Sectors4
Healthcare40.99%
Technology33.08%
Unknown18.20%
Financial Services7.73%

Behavioral investing profile

Checking access…
Concentrated Value- primarily Healthcare, Technology, Unknown
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Below Average(2.0 / 5.0)
Holdings P&L45
Conviction36
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

No active accumulation streaks detected for this filer.

Streaks require 2+ consecutive quarters of increased positions in the most recent period.

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used